
Gautam Jha, MD, and Emmanuel Antonarakis, MD, on the advantages of collaborative efforts between community and academic oncologists.

Your AI-Trained Oncology Knowledge Connection!


Gautam Jha, MD, and Emmanuel Antonarakis, MD, on the advantages of collaborative efforts between community and academic oncologists.

Ricardo D. Parrondo, MD, discusses the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

Ilyas Sahin, MD, discusses the potential utility of Northstar Response assay in patients with advanced gastrointestinal cancer.

Raj Singh, MD, discusses treating patients with lung cancer with CNS metastases.

Jaime R. Merchán, MD, discusses the current roles for immunotherapy and TKIs in patients with renal cell carcinoma.

Saad J. Kenderian, MB, CHB, discusses ongoing research taking place to potentially move liso-cel into earlier lines of therapy for patients with CLL.

Tycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.

Minesh Mehta, MD, discusses recent advancements in radiation oncology approaches for patients with prostate cancer.

Shivaani Kummar, MD, FACP, discusses the evaluation of rezatapopt in patients with advanced solid tumors.

Andre Goy, MD, discusses updated data from the phase 2 ZUMA-2 trial, highlighting the expanded-access ZUMA-18 study in MCL.

Wenxin (Vincent) Xu, MD, highlights research in renal cell carcinoma, spotlighting developments and updates in patients with non-clear cell disease.

Guenther Koehne, MD, PhD, discusses research efforts to overcome resistance to CAR T-cell therapy in hematologic malignancies.

Alessandro Villa, DDS, PhD, MPH, discusses the incidence of oral toxicities in patients with head and neck cancer.

Joseph Mikhael, MD, discusses unmet needs that remain to be addressed in the treatment of patients with multiple myeloma.

Michael Richardson, MD, discusses escalating uterine cancer rates among Asian Americans.

Minesh Mehta, MD, discusses how MRI-guided adaptive radiation therapy systems may improve disease outcomes in cancer care.

Ruben Olivares, MD, discusses the evolving role for focal radiation therapy in the management of prostate cancer.

Phillip J. Koo, MD, discusses the use of PSMA PET imaging in prostate cancer.

Don S. Dizon, MD, on the prevalence of sexual complications in patients with breast cancer.

Gottfried Konecny, MD, discusses the MIRASOL trial that evaluated mirvetuximab soravtansine in FRα-positive platinum-resistant recurrent ovarian cancer.

Steven E. Finkelstein, MD, DABR, FACRO, on advancing radiation oncology and updates from the 2024 ACRO Summit.

Wenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.

Daniel Spratt, MD, discusses the integration of metastasis-directed therapy and hypofractionation in prostate cancer.

Jennifer R. Brown, MD, PhD, discusses results from a genomic analysis of responses with pirtobrutinib in patients with chronic lymphocytic leukemia.

Ariel Grajales-Cruz, MD, discusses research elucidating the role of teclistamab monotherapy for patients with relapsed/refractory multiple myeloma.

Daniel Spratt, MD, discusses the use of radiation therapy in low- and high-risk prostate cancer.

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.

Wenxin (Vincent) Xu, MD, discusses treatment decision-making in patients with renal cell carcinoma.

Philip J. Koo, MD, discusses the treatment of patients with prostate cancer throughout the different stages of their disease.

Reshma L. Mahtani, DO, discusses how the expansion of HER2-targeted agents has impacted the management of HER2-positive breast cancer.